View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Care Property Invest: 3 directors

Three Directors at Care Property Invest bought 6,135 shares at between 12.260EUR and 12.560EUR. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...

Martin Marandon-Carlhian ... (+3)
  • Martin Marandon-Carlhian
  • Stephane Houri
  • Steven Boumans

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/13/2024

We maintain our Outperform rating on CaixaBank, one of our Top Picks in the sector, with a higher target of € 7.2 vs € 6.7 and ahead of the CMD on 19 November. We are lifting our net income estimates by 7% for 2025-2026, to 7% above the consensus. The strategic update is set to highlight the wisdom of the business model diversification (long-term savings) to address the current transition phase on rates. Despite a solid market performance, the profile does not look to be fully reflec...

Martin Marandon-Carlhian ... (+3)
  • Martin Marandon-Carlhian
  • Stephane Houri
  • Steven Boumans

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 13/11/2024

Nous réitérons notre opinion Surperformance sur CaixaBank, l’un de nos top picks du secteur, avec un OC porté à 7.2 € vs 6.7 € et en amont du CMD du 19/11. Nous relevons nos anticipations de RN de 7% sur 2025/2026 qui ressortent 7% supérieures au consensus. L’update stratégique devrait mettre en avant la pertinence de la diversification du business model (épargne LT) face à la transition actuelle sur les taux. Malgré un solide parcours boursier, cela n’est pas pleinement reflété dans ...

Florent Laroche-Joubert ... (+3)
  • Florent Laroche-Joubert
  • Roy Külter
  • Steven Boumans

ODDO : Spain: the PSOE and SUMAR looking to abolish the SOCIMI regime

>PSOE and Sumar spring a surprise in seeking to suddenly abolish the SOCIMI regime - On Monday 11 November, the PSOE reached a tax agreement with its Spanish government ally, “Sumar”, whereby the two parties want to abolish the SOCIMI REIT regime or at least part of its tax advantages. This sudden stance, which surprised Spanish property professionals, is thus different from the position that was presented just last week, namely to “encourage the construction of affor...

Florent Laroche-Joubert ... (+3)
  • Florent Laroche-Joubert
  • Roy Külter
  • Steven Boumans

ODDO : Espagne : le PSOE et SUMAR souhaiteraient abolir le régime SOCI...

>PSOE et Sumar créent la surprise en voulant supprimer soudainement le régime SOCIMI - Ce lundi 11 novembre, le PSOE sont parvenus à un accord fiscal avec son allié au gouvernement espagnol, « Sumar », par lequel les deux partis veulent supprimer le régime SOCIMI ou au moins une partie de ses avantages fiscaux. Cette prise de position soudaine qui a crée la surprise auprès des professionnels de l’immobilier espagnol, diffère ainsi de la position qui était encore mise ...

Lynn Hautekeete
  • Lynn Hautekeete

Risk of SOCIMI abolishment Fear of the SOCIMI abolishment stresses Eur...

Yesterday Spanish media reported on the potential abolishment of the SOCIMI status. The proposal comes from PSOE (socialists) and Sumar (Left winged). This is the REIT regime for listed companies that alows for a tax exemption. If this is the case corporate income tax would increase from 0% to 25%. It is very important to note that this measure is not yet approved. There is no visiblity yet on a potential alternative system. Additionally, measurements (cost shifts) could be taken to decrease the...

Hilde Van Boxstael ... (+8)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste

Morning Notes : AALB NA, ADYEN NA, CPINV BB, CMBT BB, GBLB BB, MDXH BB...

: AALB NA, ADYEN NA, CPINV BB, CMBT BB, GBLB BB, MDXH BB, TESB BB, ALFEN NA

Lynn Hautekeete
  • Lynn Hautekeete

Care Property Invest 3Q24 results: +2% guidance increase

Care Property invest reports its 3Q24 slightly above our expectations and increases its FY24 guidance by 2% The dividend guidance remains stable at 1.0 DPS as the pay-out ratio is high. Operationally the company is performing in line with our expectations. The difference comes from slightly lower other opex (including settlement with a developer in 1Q24) and slightly lower financing costs. The debt ratio of CPINV remains high at 48.2% (excl leases at FV) or 45.5% LTV (incl leases at FV). This li...

Roy Külter ... (+2)
  • Roy Külter
  • Steven Boumans

Care Property Invest : Q3 2024 results: Upgraded EPS guidance, with st...

>EPS outlook 2% up; cost of debt down; underlying metrics remain solid - FY 2024 outlook raised +2.4%, now being adj. EPRA EPS of € 1.05 (vs €1.025 before) and the company maintains the intention to pay a gross dividend of €1.00/sh.Variations in fair value of investment properties were -/- €2.1m for 9M 2024 and flat for Q3.Indexation (like-for-like rental growth) was 1.7%, similar to H1 given the majority of leases having added indexation in January.EPR...

Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Michiel Declercq
  • Wim Lewi
Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

Hyloris Reports 1H24 preliminary results, auditor review ongoing

Hyloris reported preliminary 1H24 results with total revenues of € 4.6m (1H23: € 2.3m), which include a € 2.1m milestone payment for the launch of Maxigesic IV in the US. While a specific cash runway was not provided, the company believes it's well capitalised to fund R&D for existing products, but will require additional funding to commercialise its near-term cardiology products in the US. We reiterate our € 5 TP and Hold rating.

Christophe Chaput ... (+3)
  • Christophe Chaput
  • Florent Laroche-Joubert
  • Steven Boumans

ODDO : The recovery is only beginning and the best is yet to come

The rate cut carried out and yet to come (ECB: -125bp to -150bp to come by end-2025e) is a real driver for listed real estate and creates the conditions enabling it to outperform. In this context, we are lifting 23 target prices for the 42 stocks covered. Covivio, CTP, Merlin Properties, URW, Vonovia and Xior Student Housing are now our Top Picks. Aedifica (Outperform vs Neutral) should also benefit. Lastly, we are lowering Care Property to Neutral and SFL to Underperform. - >...

Christophe Chaput ... (+3)
  • Christophe Chaput
  • Florent Laroche-Joubert
  • Steven Boumans

ODDO : La reprise ne fait que commencer et le meilleur est à venir

La baisse de taux actée et à venir (BCE : -125 à 150 pb à venir d’ici fin 2025e) agit comme un véritable catalyseur pour l’immobilier côté et crée les conditions lui permettant de surperformer. Dans ce cadre, nous relevons 23 objectifs de cours sur 42 valeurs suivies. Covivio, CTP, Merlin Properties, URW, Vonovia et Xior Student Housing constituent désormais nos top picks. Aedifica (Surperformance vs Neutre) devrait également en bénéficier. Enfin, nous abaissons Care Property à N...

Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Wim Hoste
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

Hyloris Hyloris' partner AFT out licences Maxigesic IV in China

Hyloris announced that its partner AFT Pharmaceuticals has signed an exclusive licensing agreement for Maxigesic IV (1000mg paracetamol with 300mg ibuprofen) for China with a subsidiary of Xizang Weixinkang Pharmaceutical. Hyloris will be eligible for a share of the $300K upfront received by AFT, as well as milestones and royalties. Details on the development plans in China have not been disclosed, though we believe a local trial would likely be required to gain approval by the Chinese NMPA (nat...

Jacob Mekhael ... (+3)
  • Jacob Mekhael
  • Michiel Declercq
  • Thomas Vranken

Life Sciences Conference 26.09.2024

This conference booklet is your guide to our Life Sciences Conference set to take place on Thursday, 26 September 2024 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or join pitch sessions with the following companies and their top management: Public: AUTOLUS | GALAPAGOS | HYLORIS | INVENTIVA | MAAT PHARMA | ONWARD MEDICAL | SEQUANA MEDICAL | UCB | ZEALAND PHARMA Private: CONFO TX | MRM HEALTH | PANTERA | SKYLINE DX

Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Michiel Declercq
  • Wim Lewi
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch